The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...
Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Zacks.com on MSN10d
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowGilead Sciences (GILD) closed the most recent trading day at $88.82, moving +0.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.86% for the day. At ...
Explore the breadth of our life sciences degrees, spanning the full breadth of life sciences from molecules through to ecosystems. Learn more about the expertise of our research labs where we deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback